European Archives - Page 1042 of 1109 - European Medical Journal

Continue
EMJ
13 Jul 2015

The impact of the Oncotype DX® Recurrence Score® on treatment decisions in breast cancer patients

The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® – a number ranging from 0 to 100. This number indicates the…
EMJ
10 Jul 2015

Molecular characterisation of kidney cancer and opportunities for targeted therapies

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…
EMJ
10 Jul 2015

Emerging targeted therapies in haematological malignancies

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE…
EMJ
10 Jul 2015

New strategies in the treatment of multiple myeloma

Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the 2015 American Society of Clinical…
EMJ
10 Jul 2015

STRIDE: Phase 2 study of sipuleucel-T in metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…
EMJ
10 Jul 2015

Julie M. Vose, MD, MBA, FASCO, elected ASCO President for 2015–2016 term

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 2015–2016 term, Julie M. Vose, MD, MBA, of the…
EMJ
10 Jul 2015

Towards targeted therapy of chronic lymphocytic leukaemia

Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, summarises recent progress in the treatment of chronic lymphocytic…
EMJ
10 Jul 2015

Melanoma treatment update at ASCO 2015

Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented at the…
EMJ
10 Jul 2015

CheckMate 067: Phase 3 trial of nivolumab in melanoma

University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus…
EMJ
10 Jul 2015

COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney…
We’ve noticed you’re accessing
from North/South America.